Cited by 416Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Long-Term Follow-up of the West of Scotland Coronary Prevention Study

Open access

Ford, Ian, Murray, Heather, Packard, Chris J., Shepherd, James, Macfarlane, Peter W., Cobbe, Stuart M.·2007·New England Journal of Medicine

DOI 10.1056/nejmoa065994

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The West of Scotland Coronary Prevention Study was a randomized clinical trial comparing pravastatin with placebo in men with hypercholesterolemia who did not have a history of myocardial infarction, with an average follow-up of approximately 5 years. The combined outcome of death from definite coronary heart disease or definite nonfatal myocardial infarction was reduced from 7.9 to 5.5% (P<0.001) in the treatment group. Extended follow-up data were obtained for approximately 10 years after completion of the trial. METHODS: For the survivors of the trial, all deaths, hospitalizations and deaths due to coronary events and stroke, and incident cancers and deaths from cancer were tracked with the use of a national computerized record-linkage system. The results were analyzed with time-to-event analyses and use of Cox proportional-hazards models. RESULTS: Five years after the trial ended, 38.7% of the original statin group and 35.2% of the original placebo group were being treated with a statin. In the period approximately 10 years after completion of the trial, the risk of death from coronary heart disease or nonfatal myocardial infarction was 10.3% in the placebo group and 8.6% in the pravastatin group (P=0.02); over the entire follow-up period, the rate was 15.5% in the placebo group and 11.8% in the pravastatin group (P<0.001). Similar percentage reductions were seen in the combined rate of death from coronary heart disease and hospitalization for coronary events for both periods. The rate of death from cardiovascular causes was reduced (P=0.01), as was the rate of death from any cause (P=0.03), over the entire follow-up period. There were no excess deaths from noncardiovascular causes or excess fatal or incident cancers. CONCLUSIONS: In this analysis, 5 years of treatment with pravastatin was associated with a significant reduction in coronary events for a subsequent 10 years in men with hypercholesterolemia who did not have a history of myocardial infarction.

Integrity signals

Registry

Crossref · 10.1056/nejmoa065994

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis: The ASTEROID Trial
Nissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., et al. (2006) · JAMA · doi:10.1001/jama.295.13.jpc60002 · Cited by 2,047
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema, J., Bruschke, A. V., van Boven, A. J., Reiber, J., Bal, E., Zwinderman, A., Jansen, H., Boerma, G., van Rappard, F. M., & Kong, L. I. (1995) · Circulation · doi:10.1161/01.cir.91.10.2528 · Cited by 911
Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II)
Crouse, J. R., Byington, R. P., Bond, M. G., Espefand, M. A., Craven, T. E., Sprinkle, J. W., McGovern, M. E., & Furberg, C. D. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80580-3 · Cited by 607
Statins and Cancer Risk
Dale, K. M., Coleman, C. I., Henyan, N. N., Kluger, J., & White, C. M. (2006) · JAMA · doi:10.1001/jama.295.1.74 · Cited by 600
Antibodies against MICA Antigens and Kidney-Transplant Rejection
Zou, Y., Šťastný, P., Süsal, C., Döhler, B., & Opelz, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067160 · Cited by 452

Flagged first, then by citations

Show all 23 references

Research works printed but not linked: 2

1994, Lancet, 344, 1383
Kendrick S, 1993, Health Bull (Edinb), 51, 72

Sorted by citations

Items 101–200 of 416

Statins and the Risk of Lung Cancer: A Meta-Analysis
Tan, M., Song, X., Zhang, G., Peng, A., Li, X., Li, M., Liu, Y., & Wang, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057349 · Cited by 55
Regulatory T cells: Possible mediators for the anti-inflammatory action of statins
Shahbaz, S. K., Sadeghi, M., Koushki, K., Penson, P. E., & Sahebkar, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104469 · Cited by 58
Biochemistry of Statins
Egom, E. E. A., & Hafeez, H. (2016) · Advances in clinical chemistry · doi:10.1016/bs.acc.2015.10.005 · Cited by 57
Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
Kosmas, C. E., Estrella, A. M., Skavdis, A., Genao, E. P., Martinez, I., & Guzman, E. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s230592 · Cited by 54
Statin Use and Risk of Lung Cancer: a Meta-Analysis of Observational Studies and Randomized Controlled Trials
Wang, J., Li, C., Tao, H., Cheng, Y., Han, L., Li, X., & Hu, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077950 · Cited by 52
The Association Between Statin Use and the Diagnosis of Prostate Cancer in a Population Based Cohort
Breau, R. H., Karnes, R. J., Jacobson, D. J., McGree, M. E., Jacobsen, S. J., Nehra, A. X., Lieber, M. M., & Sauver, J. L. S. (2010) · The Journal of Urology · doi:10.1016/j.juro.2010.03.149 · Cited by 51
N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS
Welsh, P. I., Doolin, O., Willeit, P., Packard, C. J., Macfarlane, P. W., Cobbe, S. M., Gudnason, V. G., Angelantonio, E. D., Ford, I., & Sattar, N. A. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs239 · Cited by 51
Next Steps in Primary Prevention of Coronary Heart Disease
DOMANSKI, M. J., Fuster, V., Díaz‐Mitoma, F., Grundy, S. M., Lloyd‐Jones, D. M., Mamdani, M., Roberts, R. E., Thorpe, K. E., Hall, J., Udell, J. A., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.08.857 · Cited by 50
Antioxidant Effects of Statins in the Management of Cardiometabolic Disorders
Lim, S. K., & Barter, P. J. (2014) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.24398 · Cited by 53
Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review
Vonbank, A., Drexel, H., Agewall, S., Lewis, B. S., Dopheide, J. F., Kjeldsen, K. P., Ceconi, C., Savarese, G., Rosano, G. M. C., Waßmann, S., et al. (2018) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvy028 · Cited by 50
Clinical trials in crisis: Four simple methodologic fixes
Vickers, A. J. (2014) · Clinical Trials · doi:10.1177/1740774514553681 · Cited by 49
“As one well-known example, the long-term follow-up for the seminal West of Scotland Coronary Prevention Study comparing pravastatin with placebo was based entirely on routine records held by the National Health Service, including death, hospital discharges, and cancer.(23) There is empirical evidence that such an appr…”
Method
Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia
O’Donnell, T. F. X., Deery, S. E., Darling, J. D., Shean, K. E., Mittleman, M. A., Yee, G. N., Dernbach, M. R., & Schermerhorn, M. L. (2017) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2017.03.416 · Cited by 49
Pravastatin use and cancer risk: a meta‐analysis of individual patient data from long‐term prospective controlled trials in Japan
Matsushita, Y., Sugihara, M., Kaburagi, J., Ozawa, M., Iwashita, M., Yoshida, S., Saito, H., & Hattori, Y. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1870 · Cited by 48
The double-edged sword of statin immunomodulation
Goldstein, M. R., Mascitelli, L., & Pezzetta, F. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.01.023 · Cited by 49
Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria
Brouwers, F. P. J., Asselbergs, F. W., Hillege, H. L., de Boer, R. A., Gansevoort, R. T., van Veldhuisen, D. J., & van Gilst, W. H. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.03.028 · Cited by 46
Fat lowers fat: Purified phospholipids as emerging therapies for dyslipidemia
Sahebkar, A. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.01.013 · Cited by 46
Are Routinely Collected NHS Administrative Records Suitable for Endpoint Identification in Clinical Trials? Evidence from the West of Scotland Coronary Prevention Study
Barry, S., Dinnett, E. M., Kean, S., Gaw, A., & Ford, I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075379 · Cited by 44
A framework for identification of on- and off-target transcriptional responses to drug treatment
Huang, Y., Furuno, M., Arakawa, T., Takizawa, S., de Hoon, M., Suzuki, H., & Arner, E. (2019) · Scientific Reports · doi:10.1038/s41598-019-54180-4 · Cited by 47
Activator protein-1 (AP-1) signalling in human atherosclerosis: results of a systematic evaluation and intervention study
Meijer, C. A., Haen, P. A. A. L., van Dijk, R. A., Hira, M., Hamming, J. F., van Bockel, J. H., & Lindeman, J. H. N. (2011) · Clinical Science · doi:10.1042/cs20110234 · Cited by 42
Effect of statins type on incident prostate cancer risk: a meta-analysis and systematic review
Yang, L., Wei, Q., Tan, P., Zhang, C., Wei, S., Tang, Z., & Gao, L. (2017) · Asian Journal of Andrology · doi:10.4103/1008-682x.190327 · Cited by 41
Statin Therapy Prescribing for Patients with Type 2 Diabetes Mellitus: A Review of Current Evidence and Challenges
Elnaem, M. H., Mohamed, M. H. N., Huri, H. Z., Azarisman, S. M., & Elkalmi, R. M. (2017) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_30_17 · Cited by 42
“[35] It has been shown in the literature that early use of statins for primary prophylaxis was associated with higher long‐term CVD prophylaxis.[36] Further, it was reported that using statins in prediabetic individuals may confer a lower CVD risk.”
Background
Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study
Foody, J. M., Joyce, A. T., Rudolph, A. E., Liu, L. Z., & Benner, J. S. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802203279 · Cited by 43
The epidemiological concept of residual risk
Vanuzzo, D. (2011) · Internal and Emergency Medicine · doi:10.1007/s11739-011-0669-5 · Cited by 41
Evidence-based Use of Statins for Primary Prevention of Cardiovascular Disease
Minder, C. M., Blaha, M. J., Horne, A., Michos, E. D., Kaul, S., & Blumenthal, R. S. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.013 · Cited by 41
Can we dramatically reduce the incidence of coronary heart disease?
DOMANSKI, M. J., Lloyd‐Jones, D. M., Fuster, V., & Grundy, S. M. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.158 · Cited by 42
Statin use and incident prostate cancer risk: does the statin brand matter? A population-based cohort study
Lustman, A., Nakar, S., Cohen, A. D., & Vinker, S. (2013) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2013.34 · Cited by 40
Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension
Sever, P., Poulter, N. R., Dahlöf, B., & Wedel, H. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e328326cb1a · Cited by 40
The Role of Early LDL Lowering to Prevent the Onset of Atherosclerotic Disease
Ference, B. A., & Mahajan, N. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0312-1 · Cited by 41
“At the end of the 15-year total follow-up period [29], individuals originally randomized to statin therapy had a persistently lower risk of CHD, 11.”
Background
Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention
Laufs, U., Descamps, O. S., Catapano, A. L., & Packard, C. J. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu228 · Cited by 38
Liposomal prednisolone promotes macrophage lipotoxicity in experimental atherosclerosis
van der Valk, F. M., Schulte, D. M., Meiler, S. U., Tang, J., Zheng, K. H., den Bossche, J. V., Seijkens, T. T. P., Laudes, M., de Winther, M. P. J., Lutgens, E., et al. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.02.022 · Cited by 40
Statin therapy is associated with higher long-term but not perioperative survival after abdominal aortic aneurysm repair
O’Donnell, T. F. X., Deery, S. E., Shean, K. E., Mittleman, M. A., Darling, J. D., Eslami, M. H., DeMartino, R. R., & Schermerhorn, M. L. (2018) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2017.11.084 · Cited by 40
Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up†
Preiss, D., Welsh, P. I., Murray, H. M., Shepherd, J., Packard, C. J., Macfarlane, P. W., Cobbe, S. M., Ford, I., & Sattar, N. A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq095 · Cited by 40
“To help clarify the disparate literature, we related baseline FPG levels to the risk of incident CVD events, all-cause death, and the development of diabetes in the West of Scotland Coronary Prevention Study (WOSCOPS), for which 15-year follow-up data of CVD events are now available.(10)”
BackgroundInfluential
Primary prevention of cardiovascular disease with statins in the elderly
Reiner, Ž. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0420-6 · Cited by 38
Are statins really wonder drugs?
Grover, H. S., Luthra, S., & Maroo, S. (2013) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2013.05.016 · Cited by 38
Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study
Taylor, D. C. A., Pandya, A., Thompson, D., Chu, P., Graff, J. S., Shepherd, J., WENGER, N. K., Greten, H., Carmena, R., Drummond, M., et al. (2008) · The European Journal of Health Economics · doi:10.1007/s10198-008-0126-1 · Cited by 37
Understanding patients’ perspective of statin therapy: can we design a better approach to the management of dyslipidaemia? A literature review
Chee, Y. J., Chan, V., & Tan, N. C. (2014) · Singapore Medical Journal · doi:10.11622/smedj.2014099 · Cited by 37
Statin therapy and plasma cortisol concentrations: A systematic review and meta-analysis of randomized placebo-controlled trials
Sahebkar, A., Rathouska, J., Simental‐Mendía, L. E., & Nachtigal, P. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.013 · Cited by 37
“Apart from their beneficial effects in reducing cardiovascular orbidity and mortality [5], statins possess several pleiotropic ffects that are independent of the putative lipid-modifying effects”
Background
The paradox of cholesterol and stroke
Amarenco, P., & Steg, P. G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61751-6 · Cited by 37
Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis
Krane, V., Schmidt, K.-R., Gutjahr-Lengsfeld, L., Mann, J. F. E., März, W., Swoboda, F., & Wanner, C. (2016) · Kidney International · doi:10.1016/j.kint.2015.12.033 · Cited by 38
The Importance of Matching Language to Type of Evidence: Avoiding the Pitfalls of Reporting Outcomes Data
Kohli, P., & Cannon, C. P. (2012) · Clinical Cardiology · doi:10.1002/clc.22066 · Cited by 37
Baseline Low-Density Lipoprotein Cholesterol Levels and Outcome in Patients With Heart Failure
Charach, G., George, J., Roth, A., Rogowski, O., Wexler, D., Sheps, D. S., Grosskopf, I., Weintraub, M. S., Keren, G., & Rubinstein, A. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.08.660 · Cited by 36
Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality
Lim, S. K., Sakuma, I., Quon, M. J., & Koh, K. K. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.10.037 · Cited by 36
“Further, the long-term follow-up (10 years extended from the original 5 years) of the WOSCOPS demonstrates that the risk of death from coronary heart disease, nonfatal myocardial infarction, and rate of death from cardiovascular causes is significantly reduced with pravastatin treatment [36].”
Background
Adherence and persistence to hyperlipidemia medications in patients with atherosclerotic cardiovascular disease and those with diabetes mellitus based on administrative claims data in Japan
Wake, M., Oh, A., Onishi, Y., Guelfucci, F., Shimasaki, Y., & Teramoto, T. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.12.026 · Cited by 36
Simvastatin and Indomethacin Have Similar Anti‐Inflammatory Activity in a Rat Model of Acute Local Inflammation
Nežić, L., Škrbić, R., Dobrić, S., Stojiljković, M. P., Jacevic, V. M., Šatara, S. S., Milovanovic, Z. A., & Stojaković, N. (2009) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2008.00302.x · Cited by 35
Effect of antihypertensive deprescribing on hospitalisation and mortality: long-term follow-up of the OPTiMISE randomised controlled trial
Sheppard, J. P., Temple, E., Wang, A., Smith, A., Pollock, S., Ford, G. A., Hobbs, R. F., Kenealy, N., Little, P. S., Lown, M. T., et al. (2024) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(24)00131-4 · Cited by 37
Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes.
Enas, E. A., Kuruvila, A. T., Khanna, P., Pitchumoni, C. S., & Mohan, V. (2013) · Europe PMC (PubMed Central) · Cited by 34
Long-term efficacy and safety of statin treatment beyond six years: A meta-analysis of randomized controlled trials with extended follow-up
Lv, H., Jin, D., Liu, M., Liu, Y., Wang, J., & Geng, D.-F. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.02.006 · Cited by 34
Starting Primary Prevention Earlier With Statins
Robinson, J. G. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.07.076 · Cited by 34
Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trial
Kjøller, E., Hilden, J., Winkel, P., Galatius, S., Frandsen, N. J., Jensen, G. B., Hansen, J. F., Kastrup, J., Jespersen, C. M., Hildebrandt, P. R., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2013.12.032 · Cited by 34
Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis
Lu, Y., Cheng, Z., Zhao, Y., Chang, X., Chan, C., Bai, Y., & Cheng, N. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.10.025 · Cited by 35
Landmark Lipid‐Lowering Trials in the Primary Prevention of Cardiovascular Disease
Chrispin, J., Martin, S. S., Hasan, R. K., Joshi, P. H., Minder, C. M., McEvoy, J. W., Kohli, P., Johnson, A. E., Wang, L., Blaha, M. J., et al. (2013) · Clinical Cardiology · doi:10.1002/clc.22147 · Cited by 36
A Clinical Review of Statins and Cancer: Helpful or Harmful?
Gonyeau, M. J., & Yuen, D. W. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.2.177 · Cited by 33
Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
Kosmas, C. E., Silverio, D., Ovalle, J. E. G., Montan, P. D., & Guzman, E. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s149423 · Cited by 33
Ten-Year All-Cause Mortality in Presumably Healthy Subjects on Lipid-Lowering Drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort)
Gardette, V., Bongard, V., Dallongeville, J., Arveiler, D., Bingham, A., Ruidavets, J., Amouyel, P., Haas, B., Ducimetière, P., & Ferrières, J. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.09.092 · Cited by 33
Vascular memory: can we broaden the concept of the metabolic memory?
Jermendy, G. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-44 · Cited by 36
LDL-lowering therapy and the risk of prostate cancer: a meta-analysis of 6 randomized controlled trials and 36 observational studies
Tan, P., Wei, S., Tang, Z., Gao, L., Zhang, C., Nie, P., Yang, L., & Wei, Q. (2016) · Scientific Reports · doi:10.1038/srep24521 · Cited by 32
Long-term weight loss following a randomised controlled trial of a weight management programme for men delivered through professional football clubs: the Football Fans in Training follow-up study
Gray, C. M., Wyke, S., Zhang, R., Anderson, A. S., Barry, S., Brennan, G., Briggs, A. H., Boyer, N., Bunn, C., Donnachie, C., et al. (2018) · Public Health Research · doi:10.3310/phr06090 · Cited by 35
Statin and NSAID use and prostate cancer risk
Coogan, P. F., Kelly, J. P., Strom, B. L., & Rosenberg, L. A. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1970 · Cited by 32
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Tunnicliffe, D. J., Palmer, S. C., Cashmore, B. A., Saglimbene, V. M., Krishnasamy, R., Lambert, K., Johnson, D. W., Craig, J. C., & Strippoli, G. F. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784.pub3 · Cited by 39
Association of dyslipidaemia with cholilithiasis and effect of cholecystectomy on the same
Malik, A. A., Wani, M. L., Tak, S. I., Irshad, I., & Ul-Hassan, N. (2011) · International Journal of Surgery · doi:10.1016/j.ijsu.2011.08.003 · Cited by 31
How to balance cardiorenometabolic benefits and risks of statins
Lim, S. K., Oh, P. C., Sakuma, I., & Koh, K. K. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.06.001 · Cited by 31
Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence
Gupta, K. K., Ali, S., & Sanghera, R. S. (2018) · Cardiology and Therapy · doi:10.1007/s40119-018-0123-0 · Cited by 35
Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump Inhibitors
Joo, M. K., Park, J., & Chun, H. J. (2017) · Digestive Diseases · doi:10.1159/000480149 · Cited by 30
Do Statins Prevent or Promote Cancer?
Goldstein, M. R., Mascitelli, L., & Pezzetta, F. (2008) · Current Oncology · doi:10.3747/co.v15i2.235 · Cited by 32
Comparison of the Effect of Lipophilic and Hydrophilic Statins on Serum Adiponectin Levels in Patients with Mild Hypertension and Dyslipidemia: Kinki Adiponectin Interventional (KAI) Study
Kai, T., Arima, S., Taniyama, Y., Nakabou, M., & Kanamasa, K. (2008) · Clinical and Experimental Hypertension · doi:10.1080/10641960802251925 · Cited by 30
“It has been reported that statins have carry-over effects (59).”
Background
Long term extension of a randomised controlled trial of probiotics using electronic health records
Davies, G. I., Jordan, S. E., Brooks, C. J., Thayer, D. S., Storey, M., Morgan, G., Allen, S. J., Garaiová, I., Plummer, S. F., & Gravenor, M. B. (2018) · Scientific Reports · doi:10.1038/s41598-018-25954-z · Cited by 30
The Framingham Study on Cardiovascular Disease Risk and Stress-Defenses: A Historical Review
Abohelwa, M., Kopel, J. J., Shurmur, S. W., Ansari, M. M., Awasthi, S., & Awasthi, S. (2023) · Journal of Vascular Diseases · doi:10.3390/jvd2010010 · Cited by 43
The Role of Aspirin, Vitamin D, Exercise, Diet, Statins, and Metformin in the Prevention and Treatment of Colorectal Cancer
Sehdev, A., & O’Neil, B. H. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0359-z · Cited by 28
Low Levels of Low-Density Lipoprotein Cholesterol: A Negative Predictor of Survival in Elderly Patients with Advanced Heart Failure
Charach, G., Rabinovich, A., Argov, O., Wexler, D., Sheps, D. S., Charach, L., Weintraub, M. S., & George, J. (2013) · Cardiology · doi:10.1159/000355164 · Cited by 29
Legacy effect of statins: 20-year follow up of the West of Scotland Coronary Prevention Study (WOSCOPS)
Kashef, A., & Giugliano, G. R. (2017) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2016.35 · Cited by 30
Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care versus celecoxib outcome trial (SCOT)
MacDonald, T. M., Mackenzie, I. S., Wei, L., Hawkey, C. J., & Ford, I. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002295 · Cited by 29
Effect of Use of Combination Evidence-Based Medical Therapy After Acute Coronary Syndromes on Long-Term Outcomes
Lahoud, R. N., Howe, M., Krishnan, S. M., Zacharias, S. K., & Jackson, E. A. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.08.024 · Cited by 28
Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia: the integration of ezetimibe and bempedoic acid may enhance goal attainment
Parhofer, K. G., Aguíar, C., Banach, M., Drexel, H., Gouni‐Berthold, I., de Isla, L. P., Rietzschel, E. R., Zambon, A., & Ray, K. K. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf007 · Cited by 31
Statins: Do They Have a Potential Role in Cancer Prevention and Modifying Cancer-Related Outcomes?
Bonovas, S. (2014) · Drugs · doi:10.1007/s40265-014-0309-2 · Cited by 27
Long‐Term Follow‐Up of Moderately Hypercholesterolemic Hypertensive Patients Following Randomization to Pravastatin vs Usual Care: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial ( ALLHAT ‐ LLT )
Margolis, K. L., Davis, B. R., Baimbridge, C., Ciocon, J. O., Cuyjet, A. B., Dart, R. A., Einhorn, P. T., Ford, C. E., Gordon, D., Hartney, T. J., et al. (2013) · Journal of Clinical Hypertension · doi:10.1111/jch.12139 · Cited by 27
Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial
Ohsfeldt, R. L., Gandhi, S. K., Smolen, L. J., Jensen, M. M., Fox, K. M., Gold, A., & Hsia, J. A. (2010) · Journal of Medical Economics · doi:10.3111/13696998.2010.499758 · Cited by 27
Primary Prevention of Coronary Artery Disease
DOMANSKI, M. J. (2007) · New England Journal of Medicine · doi:10.1056/nejme078183 · Cited by 27
Intermediate-Term Efficacy and Tolerance of Statins in Children
Mamann, N., Lemale, J., Karsenty, A., Dubern, B., Girardet, J.-P., & Tounian, P. (2019) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2019.03.032 · Cited by 26
Degree of Joint Risk Factor Control and Incident Heart Failure in Hypertensive Patients
Kou, M., Wang, X., Ma, H., Li, X., Heianza, Y., & Qi, L. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.01.006 · Cited by 26
Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients
Ku, J. H., Jeong, C. W., Park, Y. H., Cho, M., Kwak, C. H., & Kim, H. H. (2010) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2010.39 · Cited by 26
CATheter Infections in CHildren (CATCH): a randomised controlled trial and economic evaluation comparing impregnated and standard central venous catheters in children.
Harron, K., Mok, Q., Dwan, K., Ridyard, C., Moitt, T., Millar, M., Ramnarayan, P., Tibby, S., Muller-Pebody, B., Hughes, D., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20180 · Cited by 26
Lipid-Lowering Therapy after Acute Coronary Syndrome
Pogran, E., Burger, A. L., Zweiker, D., Kaufmann, C. C., Muthspiel, M., Rega‐Kaun, G., Wenkstetten-Holub, A., Wojta, J., Drexel, H., & Huber, K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072043 · Cited by 27
Differential Metabolic Actions of Specific Statins: Clinical and Therapeutic Considerations
Lim, S. K., Sakuma, I., Quon, M. J., & Koh, K. K. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5531 · Cited by 25
Association between Statin Use and Gastric Cancer: A Nested Case-Control Study Using a National Health Screening Cohort in Korea
Kwon, M. J., Kang, H. S., Kim, J., Kim, J. H., Kim, S. H., Kim, N. Y., Nam, E. S., Min, K., & Choi, H. G. (2021) · Pharmaceuticals · doi:10.3390/ph14121283 · Cited by 24
Long-term follow-up of lipid-lowering trials
Packard, C. J., & Ford, I. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000230 · Cited by 24
Sports and exercise medicine in undergraduate training
Jaques, R., & Loosemore, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60992-1 · Cited by 23
Non-Adherence to Ivabradine and Placebo and Outcomes in Chronic Heart Failure: An Analysis from SHIFT
Böhm, M., Lloyd, S. M., Ford, I., BORER, J. S., Ewen, S., Laufs, U., Mahfoud, F., Lopez-Sendon, J. L., Ponikowski, P. P., Tavazzi, L., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.493 · Cited by 23
Best Treatment Strategies With Statins to Maximize the Cardiometabolic Benefits
Cho, K. I., Sakuma, I., Sohn, I. S., Hayashi, T., Shimada, K., & Koh, K. K. (2018) · Circulation Journal · doi:10.1253/circj.cj-17-1445 · Cited by 23
Continuation of mortality reduction after the end of randomized therapy in clinical trials of lipid-lowering therapy
Kostis, W. J., Moreyra, A. E., Cheng, J., Dobrzynski, J. M., & Kostis, J. B. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.01.006 · Cited by 23
Protocol for a randomised controlled trial of treatment of asymptomatic candidiasis for the prevention of preterm birth [ACTRN12610000607077]
Roberts, C. L., Morris, J. M., Rickard, K., Giles, W. B., Simpson, J. M., Kotsiou, G., & Bowen, J. R. (2011) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-11-19 · Cited by 23
“This is a novel and cost-efficient approach [ 51 ].”
Beyond statins: what to expect from add-on lipid regulating therapy?
Laufs, U., Weintraub, W., & Packard, C. J. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht213 · Cited by 22
A non-randomised controlled pilot study of clinical pharmacist collaborative intervention for community dwelling patients with COPD
Hunt, V., Anderson, D., Lowrie, R., Sardar, C. M., Ballantyne, S., Bryson, G., Kyle, J., & Hanlon, P. (2018) · npj Primary Care Respiratory Medicine · doi:10.1038/s41533-018-0105-7 · Cited by 22
Analysis of serum lipid profile in cholelithiasis patients.
Batajoo, H., & Hazra, N. K. (2013) · Journal of Nepal Health Research Council · doi:10.33314/jnhrc.v0i0.345 · Cited by 22
Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US
Rosen, V. M., Taylor, D. C. A., Parekh, H., Pandya, A., Thompson, D., Kuznik, A., Waters, D. D., Drummond, M., & Weinstein, M. C. (2009) · PharmacoEconomics · doi:10.2165/11531440-000000000-00000 · Cited by 21
Reduced LDL-cholesterol levels in patients with coronary artery disease are paralelled by improved endothelial function: An observational study in patients from 2003 and 2007
Delles, C., Dymott, J. A., Neisius, U., Rocchiccioli, P., Bryce, G. J., Moreno, M. U., Carty, D., Berg, G. A., Hamilton, C. A., & Dominiczak, A. F. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.01.014 · Cited by 22
Statin Therapy in Young Adults
Pletcher, M. J., & Hulley, S. B. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.018 · Cited by 22
Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events
Gandhi, S. K., Gandhi, S. K., Fox, K. M., Smolen, Jensen, OLSSON, A. G., & Paulsson (2012) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s26621 · Cited by 21
Lifelong benefits on myocardial infarction mortality: 40‐year follow‐up of the randomized Oslo diet and antismoking study
Holme, I., Retterstøl, K., Norum, K. R., & Hjermann, I. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12485 · Cited by 21
Temporal trends and forecasting of COVID-19 hospitalisations and deaths in Scotland using a national real-time patient-level data platform: a statistical modelling study
Simpson, C. R., Robertson, C., Vasileiou, E., Moore, E., McCowan, C., Agrawal, U., Stagg, H. R., Docherty, A. B., Mulholland, R. H., Murray, J., et al. (2021) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00105-9 · Cited by 22
Statins and the risk of Parkinson disease: an update on the controversy
Becker, C., & Meier, C. R. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330902859956 · Cited by 21

Authors: Ford, I., Murray, H., Packard, C. J., Shepherd, J., Macfarlane, P. W., & Cobbe, S. M.
Affiliations: University of Glasgow (GB)
ORCID: Ford, Ian
Packard, Chris J.
Macfarlane, Peter W.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2007-10-11
Volume: 357
Issue: 15
Pages: 1477-1486
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa065994
OpenAlex: W1973491874
Cited by: 416
References: 23
Citations by year: 2026: 4 · 2025: 6 · 2024: 7 · 2023: 7 · 2022: 9 · 2021: 9 · 2020: 7 · 2019: 14 · 2018: 23 · 2017: 26 · 2016: 29 · 2015: 19 · 2014: 34 · 2013: 46 · 2012: 28
FWCI: 36.61
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: pravastatin, statins, hypercholesterolemia, coronary artery disease, myocardial infarction, long-term follow-up, secondary prevention, cardiovascular mortality, cancer incidence, men
MeSH terms: Anticholesteremic Agents, Coronary Disease, Follow-Up Studies, Humans, Hypercholesterolemia, Male, Middle Aged, Myocardial Infarction, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Long-Term Follow-up of the West of Scotland Coronary Prevention Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks